Trending...
- Thru-hikers Launch New Nature Streaming TV Channel for Nature Lovers
- Gov. Wolf: Pennsylvania has Reached a Milestone in Its Plan to Vaccinate Seniors in Care
- Pennsylvania: First Lady Frances Wolf Discusses Resiliency of PA Small Business Community and Highlights Resources for Support
PLYMOUTH MEETING, Pa., Jan. 25, 2021 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the closing of its previously announced underwritten public offering of 20,355,000 shares of its common stock, which includes 2,655,000 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $8.50 per share. The gross proceeds to INOVIO from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $173 million.
BofA Securities, Jefferies and Cantor acted as joint book-running managers for the offering. Oppenheimer & Co. acted as lead manager for the offering. The Benchmark Company, Maxim Group LLC and National Securities Corporation acted as co-managers for the offering.
The shares were offered by INOVIO pursuant to a shelf registration statement filed by INOVIO with the Securities and Exchange Commission (SEC) that became automatically effective on January 20, 2021. This offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC's website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting: BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255, or by email at [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by e-mail at [email protected]; or Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th floor, New York, NY 10022; Email: [email protected].
More on The PennZone
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About INOVIO
INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. Also in development are programs targeting HPV-related cancers and a rare HPV-related disease, recurrent respiratory papillomatosis; non-HPV-related cancers glioblastoma multiforme and prostate cancer; as well as externally funded infectious disease DNA vaccine development programs in coronaviruses associated with COVID-19 and MERS diseases, Zika, Lassa fever, Ebola and HIV.
CONTACTS:
Media: Jeff Richardson, 267-440-4211, [email protected]
More on The PennZone
Investors: Ben Matone, 484-362-0076, [email protected]
SOURCE INOVIO Pharmaceuticals, Inc.
Related Links
http://www.inovio.com
BofA Securities, Jefferies and Cantor acted as joint book-running managers for the offering. Oppenheimer & Co. acted as lead manager for the offering. The Benchmark Company, Maxim Group LLC and National Securities Corporation acted as co-managers for the offering.
The shares were offered by INOVIO pursuant to a shelf registration statement filed by INOVIO with the Securities and Exchange Commission (SEC) that became automatically effective on January 20, 2021. This offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC's website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting: BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255, or by email at [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by e-mail at [email protected]; or Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th floor, New York, NY 10022; Email: [email protected].
More on The PennZone
- Keystone Expands in Kansas With C&W Insurance
- Pennsylvania: Gov. Wolf Revises Mitigation Order on Gatherings and Lifts Out-of-State Travel Restrictions
- Pennsylvania: Gov. Wolf Signs 310 Pardons; 69 as Part of the Expedited Review Program for Non-Violent Marijuana-Related Offenses
- Florida small town festival ranks Top 50 BEST in nation
- TVS Vintage Network Goes Live as TVS Television Network Lauches 40th Streaming Free to View Channel
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About INOVIO
INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. Also in development are programs targeting HPV-related cancers and a rare HPV-related disease, recurrent respiratory papillomatosis; non-HPV-related cancers glioblastoma multiforme and prostate cancer; as well as externally funded infectious disease DNA vaccine development programs in coronaviruses associated with COVID-19 and MERS diseases, Zika, Lassa fever, Ebola and HIV.
CONTACTS:
Media: Jeff Richardson, 267-440-4211, [email protected]
More on The PennZone
- Delray Beach Branding Agency Celebrates Women in Business on International Women's Day
- Digital Cash Processing, Genmega Partner to Deliver Next Generation ATM Functionality
- PPG Appoints John Bruno as Vice President, Investor Relations
- Nationally Syndicated Radio Show "Radio Bassment" Launching Daily Programming 7 Days a Week
- Instem Announces Acquisition of The Edge; Extends Reach within Discovery R&D
Investors: Ben Matone, 484-362-0076, [email protected]
SOURCE INOVIO Pharmaceuticals, Inc.
Related Links
http://www.inovio.com
Filed Under: Business
0 Comments
Latest on The PennZone
- Bentley Systems Acquires Australian Civil Construction Software Leader E7
- Settlement Unanimously Approved in Pennsylvania American Water Rate Request
- Same-Day Crowns & Affordable Dental Implants Available from Castle Dental
- Orthodontist in Harrisburg Accepting New Patients; Braces Only $3,995
- Sandline Global Fortifies World-Class Executive Team: Glenn Hopper Joins as Chief Financial Officer
- Syxsense Announces Integration with Microsoft Office 365
- USA Technologies Announces $55 Million Common Stock Investment from Multiple Investors
- Launch of Trace One E-Sourcing Will Boost Retailers' Private Label Speed to Market
- TVS Consumer Direct.Com Expands to Five Streaming Home Shopping Channels on WatchYour.TV
- Thru-hikers Launch New Nature Streaming TV Channel for Nature Lovers
- INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Velodyne Lidar, Inc. (VLDR) on Behalf of Investors
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Apache Corporation (APA) on Behalf of Investors
- Bronx DWI Lawyer Announces New Website
- Recording Artist "Cherne" Crystal Brown auditions for Sony Music, Atlantic Records and Capitol Records and it doesn't stop there
- Dental Implants Available from Springfield Dentist Starting at Only $750
- Pennsylvania: First Lady Frances Wolf Discusses Resiliency of PA Small Business Community and Highlights Resources for Support
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT) Investors
- Honorary Oscar-Winner Charles Burnett brings his award winning film on COVID-19 / Black Hollywood to the Prestigious Pan African 2021 Film Festival
- In a year of recession, Lantek closes 2020 with record sales figures and customer numbers
- Ready® Strengthens Collegiate Footprint, Announces Major Sports Drink Expansion